The aim of this study was to assess the effects of different proton pump inhibitors (PPIs) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel.
The co-administration of proton pump inhibitors (PPI) with clopidogrel reduces the risk for gastrointestinal bleeding associated with the antiplatelet effects of clopidogrel (1) . There are conflicting data as to whether PPIs have the potential to reduce the effectiveness of clopidogrel (1) . Clopidogrel is a prodrug that requires metabolism by hepatic cytochrome P450 (CYP) enzymes, including CYP2C19, to an active metabolite that blocks platelet P2Y 12 adenosine diphosphate (ADP) receptors. Because PPIs are known inhibitors of CYP2C19 (1), they may prevent the conversion of clopidogrel to its active metabolite (clopidogrel AM ). However, because not all PPIs inhibit CYP2C19 to the same extent (2) (3) (4) , the potential for a clinically relevant drug-drug interaction with clopidogrel may not be generalized to all PPIs. The present randomized, open-label, 2-period, crossover study was therefore designed to determine the effects of 4 different PPIs (dexlansoprazole, lansoprazole, omeprazole, and esomeprazole) on the steady-state pharmacokinetics (PK) and pharmacodynamics (PD) of clopidogrel.
Methods
The study design, enrollment criteria, clopidogrel PK and PD, and statistics are described in detail in the Online Appendix. To eliminate variables known to influence clopidogrel and/or PPI metabolism, homozygous CYP2C19 extensive metabolizer genotype healthy subjects were enrolled and confined in a clinical research unit.
Results
Study population. The disposition of subjects is shown in Online Figure 1 . Demographic characteristics of the 160 subjects who were randomized to receive study drug are shown in Table 1 . One hundred fifty subjects completed study drug and all study visits (Online Fig. 1 ). PK of clopidogrel in the presence and absence of PPIs. Clinically relevant daily doses of clopidogrel (75 mg), dexlansoprazole (60 mg), lansoprazole (30 mg), and esomeprazole (40 mg) were used, and the timing of PPI dosing relative to clopidogrel was adjusted to synchronize times to reach peak concentration. Omeprazole 80 mg/day, a potent inhibitor of CYP2C19, was used as a positive control for the interaction of a PPI with clopidogrel PK. As expected, peak plasma concentration of clopidogrel AM and area under the plasma concentration-time curve (AUC t ) were lower when clopidogrel was administered with omeprazole 80 mg compared with clopidogrel alone ( Clopidogrel AM AUC t on day 9 of the administration of clopidogrel with dexlansoprazole or lansoprazole was similar to that observed on day 9 of the administration of clopidogrel alone ( Table 2 , Fig. 1 ). In contrast, clopidogrel AM AUC t on day 9 of the administration of clopidogrel with esomeprazole was reduced compared with that observed at 9 days of the administration of clopidogrel alone ( Fig. 1B , Table 2 ).
Relative to clopidogrel alone, all PPIs decreased the peak plasma concentration of clopidogrel AM (omeprazole Ͼ esomeprazole Ͼ lansoprazole Ͼ dexlansoprazole) (Figs. 1C and 1D).
Clopidogrel was rapidly absorbed (median time to reach peak concentration for intact clopidogrel 1 h), and this was unaffected by lansoprazole, dexlansoprazole, omeprazole, or esomeprazole (data not shown).
PD of clopidogrel in the presence and absence of PPIs.
Omeprazole 80 mg, the positive control, when coadministered with clopidogrel, caused significant changes in vasodilatorstimulated phosphoprotein (VASP) platelet reactivity index (PRI), light transmission aggregation maximal platelet aggregation (MPA), and VerifyNow P2Y12 (Accumetrics, Inc., San Diego, CA) platelet response units (PRU) compared with clopidogrel alone (Figs. 2, 3, and 4, Tables 3, 4, and 5).
VASP P2Y 12 ASSAY. The least squares mean differences in VASP PRI 24 h after 9 days administration of clopidogrel with lansoprazole or clopidogrel with dexlansoprazole compared with clopidogrel alone were small (4.1% and 2.0%, respectively) with 90% confidence interval upper boundaries Ͻ15% ( Table 3 , Fig. 2 ), that is, less than the pre-specified upper no-effect boundary. In contrast, the difference in VASP PRI 24 h after 9 days administration of clopidogrel with esomeprazole compared with clopidogrel alone was larger, 11.4%, and its 90% confidence interval upper boundary, 15.71%, extended beyond the upper no-effect boundary of 15% (Table 3 , Fig. 2 ). The magnitude of the change in VASP PRI with esomeprazole (11.4%) was similar to that observed with omeprazole (11.0%).
LIGHT TRANSMISSION AGGREGATION. MPA in response to ADP 5 mol/l 24h after 9 days coadministration of clopidogrel with dexlansoprazole was not significantly different from MPA after clopidogrel alone. As with dexlansoprazole, the difference in MPA after clopidogrel with lansoprazole compared with clopidogrel alone was also small but, unlike that with dexlansoprazole, was statistically significant. Similar results for both dexlanso-and is a research collaborator with PLx Pharma and Takeda and served as the Chair of the COGENT trial. Dr. Michelson has been a member of the data safety monitoring boards of clinical trials sponsored by Eli Lilly/Daiichi Sankyo and Sanofi Aventis/Bristol-Myers Squibb. All other authors have reported that they have no relationship relevant to the contents of this paper to disclose.
Manuscript Frelinger et al. April 3, 2012 April 3, :1304 PPI Effects on Clopidogrel PK and PD prazole and lansoprazole were observed when ADP 20 mol/l was used as the agonist for platelet aggregation (Table 4 ). In contrast, the coadministration of esomeprazole with clopidogrel led to larger increases in ADP 5 mol/l MPA, which was similar to the least squares mean difference observed with versus without the positive control, omeprazole (Table 4) . Likewise, large, numerically similar differences were seen for both omeprazole and esomeprazole when ADP 20 mol/l was used as the agonist for platelet aggregation (Table 4 ). Similar results were obtained analyzing the percent inhibition of platelet aggregation (Table 4 ).
VERIFYNOW P2Y12 ASSAY. Compared with clopidogrel alone, the increases in PRU when clopidogrel was coadministered with dexlansoprazole, lansoprazole, omeprazole, or esomeprazole were statistically significant; however, these changes were greatest for omeprazole and esomeprazole compared with dexlansoprazole and lansoprazole ( Table 5 ). Results using VerifyNow P2Y12 percent inhibition to assess the effect of clopidogrel with and without PPIs were similar to results obtained using PRU (Online Table 5 ). Values are median Ϯ minimum/maximum (n) for Tmax and mean Ϯ SD (n) for C max and AUC t . *Point estimates for ratios of the central values for the natural logarithms of C max and AUC t . The pre-specified lower no-effect boundary limit for the 90% CI of the ratio was 0.80, and the upper no-effect boundary limit was 1.25. AUC t ϭ area under the plasma concentration-time curve; CI ϭ confidence interval; clopidogrel AM ϭ clopidogrel active metabolite; C max ϭ peak plasma concentration; PPI ϭ proton pump inhibitor; Tmax ϭ time to reach peak concentration. (5) of VASP PRI Ͼ50%, MPA 5 mol/l ADP Ͼ46%, and PRU Ն236 was not significantly different 24 h after 9 days administration of clopidogrel with lansoprazole or dexlansoprazole compared with the administration of clopidogrel alone (Table 6 ). In contrast, 24 h after 9 days administration of clopidogrel with omeprazole, HPR by VASP PRI and VerifyNow P2Y12 PRU was significantly increased and, by MPA, approached significance compared with that after clopidogrel alone. Additionally, HPR as defined by VASP and MPA 5 mol/l ADP was significantly greater 24 h after 9 days administration of clopidogrel with esomeprazole than after clopidogrel alone (Table 6 ).
HIGH ON-TREATMENT PLATELET REACTIVITY (HPR

Discussion
The main PK findings are as follows. 1) The study design and assay methods were appropriate to detect the effects of PPIs on clopidogrel PK parameters, as evidenced by significant effects of coadministered omeprazole 80 mg. 2) Clopidogrel AM AUC t values were equivalent when clopidogrel was coadministered with or without dexlansoprazole 60 mg or lansoprazole 30 mg, whereas clopidogrel AM AUC t values were decreased when clopidogrel was coadministered with omeprazole 80 mg or esomeprazole 40 mg compared with clopidogrel alone. 3) All tested PPIs significantly decreased peak plasma concentrations of clopidogrel AM , but esomeprazole and omeprazole did so to a greater degree than lansoprazole and dexlansoprazole. 4) Clopidogrel AM times to reach peak concentration were not altered by any of the PPIs tested.
The main PD findings of this study are as follows. 1) The study design and assay methods were appropriate to detect the effects of PPIs on clopidogrel PD parameters, as evidenced by significant effects of coadministered omeprazole 80 mg on VASP P2Y 12 PRI in Clopidogrel-Treated Subjects With and Without 9 Days of PPI Coadministration clopidogrel inhibition of VASP PRI, light transmission aggregation MPA, and VerifyNow P2Y12 PRU. 2) VASP PRI values were not different when clopidogrel was coadministered with or without dexlansoprazole or lansoprazole, whereas VASP PRI values were greater than the pre-specified no-effect limit when clopidogrel was coadministered with omeprazole or esomeprazole.
3) The coadministration of dexlansoprazole did not have a significant effect on MPA, while the coadministration of lansoprazole had a small effect on MPA, numerically similar to that of dexlansoprazole but statistically significant compared with that of clopidogrel alone. In contrast, omeprazole and esomeprazole had larger, numerically similar, highly significant effects on MPA. 4) All PPIs tested significantly reduced clopidogrel inhibition of VerifyNow P2Y12 PRU. However, the magnitudes of the effects of dexlansoprazole or lansoprazole on VerifyNow P2Y12 PRU were approximately one-third as large as the effects of omeprazole or esomeprazole. By 3 distinct platelet function assays, the frequency of subjects who would be categorized as at risk for ischemic or thrombotic events after percutaneous coronary intervention using the consensus group cutoffs (5) was unchanged by the coadministration of dexlansoprazole or lansoprazole with clopidogrel but increased by the coadministration of omeprazole or esomeprazole with clopidogrel (Table 6 ).
In addition to a drug-drug interaction via CYP2C19, it has been proposed that PPIs may induce drug interactions by elevating gastric pH and altering drug absorption rates (1) . The present study demonstrates that the rapid absorption of clopidogrel is unaffected by lansoprazole, dexlansoprazole, omeprazole, or esomeprazole. Study strengths. This study's randomized, 2-period, crossover design was a strength, as were enrollment criteria eliminating variables known to influence clopidogrel and/or PPI metabolism, including CYP2C19 polymorphisms and provided a uniform study population. Subjects were confined and received a standardized, restricted diet, eliminating potential confounding factors (including smoking, concurrent medications, and noncompliance with drug administration). Finally, the study was well powered to detect both PK and PD effects, as demonstrated by the statistically significant effects of the positive control (omeprazole 80 mg). Study limitations. Results for omeprazole 80 mg do not necessarily apply to the more commonly used doses of 20 and 40 mg. Also, this study was conducted in confined healthy volunteers, not patients, because this enabled us to use a randomized, crossover design while controlling for concurrent medications, diet, smoking, exercise, and other factors. Last, for uniformity, this study included only Platelet Aggregation Measured by VerifyNow P2Y12 PRU in Clopidogrel-Treated Subjects With and Without 9 Days of PPI Coadministration homozygous CYP2C19 wt/wt extensive metabolizers; consequently, our conclusions are limited to this population.
Conclusions
In this randomized, open-label, 2-period, crossover study of healthy subjects, generation of clopidogrel AM and inhibition of platelet function were reduced less by the coadministration of dexlansoprazole or lansoprazole with clopidogrel than by the coadministration of esomeprazole or omeprazole. These results suggest that the potential of PPIs to attenuate clopidogrel efficacy could be minimized by the use of dexlansoprazole or lansoprazole rather than esomeprazole or omeprazole.
